Regulation of p53 stability by Mdm2

Nature

Volumn 387, Issue 6630, 1997, Pages 299-303

  Kubbutat, Michael H G ^a   Jones, Stephen N ^b   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DNA DAMAGE; GROWTH INHIBITION; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ACETYLCYSTEINE; ANIMALS; CELL LINE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; MICE; MULTIENZYME COMPLEXES; MUTATION; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0030965946     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/387299a0     Document Type: Article

References (30)

1. Bates, S. & Vousden, K. H. p53 in signalling checkpoint arrest or apoptosis. Current Opin. Genet. Dev. 6, 1-7 (1996).
2. Barak, Y. & Oren, M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 11, 2115-2121 (1992).
3. Momand, J., Zambetti, G. P., George, D. L. & Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992).
4. Chen, J. D., Marechal, V. & Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13, 4107-4114 (1993).
5. Haupt, Y., Barak, Y. & Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15, 1596-1606 (1996).
6. Chen, J., Wu, X., Lin, J. & Levine, A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16, 2445-2452 (1996).
7. Barak, Y., Juven, T., Haffner, R. & Oren, M. mdm-2 expression is induced by wild type p53 activity. EMBO J. 12, 461-468 (1993).
8. Wu, X. W., Bayle, J. H., Olson, D. & Levine, A. J. The p53 mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993).
9. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378, 203-206 (1995).
10. Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embyonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208 (1995).
11. Xiao, Z.-X. et al. Interaction between the retinoblasmoma protein and the oncoprotein MDM2. Nature 375, 694-697 (1995).
12. Martin, K. et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375, 691-694 (1995).
13. Marston, N. J., Crook, T. & Vousden, K. H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9, 2707-2716 (1994).
14. Lin, J., Chen, J., Elenbaas, B. & Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246 (1994).
15. Lees-Miller, S. P., Sakaguchi, K., Ullrich, S. J., Appella, E. & Anderson, C. W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12, 5041-5049 (1992).
16. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
17. Hubbert, N. L., Sedman, S. A. & Schiller, J. T. Human papillomavirus type 16 E6 increases the degradatin rate of p53 in human keratinocytes. J. Virol. 66, 6237-6241 (1992).
18. Jones, S. N. et al. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc. Natl Acad. Sci. USA 93, 14106-14111 (1996).
19. Wrede, D., Tidy, J. A., Crook, T., Lane, D. & Vousden, K. H. Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol. Carcinog. 4, 171-175 (1991).
20. Maki, C. G., Huibregtse, J. & Howley, P. M. In vivo ubiquitination and proteosome-mediated degradation of p53. Cancer Res. 56, 2649-2654 (1996).
21. Kubbutat, M. H. G. & Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17, 460-468 (1997).
22. Fenteany, G. et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacytin. Science 268, 726-731 (1995).
23. Oliner, J. D. et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 (1993).
24. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
25. Di Leonardo, A., Linke, S. P., Clarkin, K. & Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551 (1994).
26. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. & Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA 90, 11623-11627 (1993).
27. Chen, C. Y. et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sci. USA 91, 2684-2688 (1994).
28. Marston, N. J. Mutational Analysis of the Tumour Suppressor Protein p53. Thesis, Univ. London (1996).
29. Marston, N. J., Jenkins, J. R. & Vousden, K. H. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10, 1707-1715 (1995).
30. Rowan, S. et al. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J. 15, 827-838 (1996).